

Special Issue

Transcription Factors as Therapeutic Targets II

Message from the Guest Editor

Deregulation of transcription factor genes are frequently observed in various human diseases. Understanding the molecular pathogenesis as well as the development of therapeutic approaches are crucial to further advance the treatment outcome. Although the feasibility of transcription factors as therapeutic targets has long been realized, the development of drugs is still very challenging due to several pharmacological and biological reasons. Therefore, an improved knowledge is necessary to make transcription factors “actionable”. The second edition of this Special Issue aims to provide a forum for the dissemination of the latest information on new approaches and methods targeting transcription factors, and with methods of testing their success in cancer or other human diseases.

Guest Editor

Dr. Takaomi Sanda

1. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
2. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Deadline for manuscript submissions

closed (30 April 2021)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/25061

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).